Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma.
Saved in:
| Title: | Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma. |
|---|---|
| Authors: | Papathanasiou T; Clinical Pharmacology, Modeling and Simulation, GSK, Baar, Switzerland. theo.x.papathanasiou@gsk.com., Kaullen J; Certara, Radnor, PA, USA., Polireddy K; Certara, Radnor, PA, USA., Chen X; Clinical Pharmacology, Modeling and Simulation, GSK, Collegeville, PA, USA., Ho YL; Clinical Pharmacology, Modeling and Simulation, GSK, Collegeville, PA, USA., Taylor A; Certara, Radnor, PA, USA., Struemper H; Clinical Pharmacology, Modeling and Simulation, GSK, Durham, NC, USA., Carreño F; Clinical Pharmacology, Modeling and Simulation, GSK, Collegeville, PA, USA., Ferron-Brady G; Clinical Pharmacology, Modeling and Simulation, GSK, Collegeville, PA, USA. |
| Source: | Clinical pharmacokinetics [Clin Pharmacokinet] 2025 Jun; Vol. 64 (6), pp. 925-942. Date of Electronic Publication: 2025 May 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Adis, part of Springer Science+Business Media Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
